Sotalex80 mg

Indications

Sotalex is an antiarrhythmic agent with combined beta-adrenergic blocking (Class II) andpotassium-channel blocking (Class III) activity. Its approved and evidence-based uses are:

• Established/FDA-approved use: Treatment of documented, life-threateningsustained ventricular arrhythmias (e.g., sustained ventricular tachycardia), because of the risk ofproarrhythmia associated with Sotalex, its use is generally reserved for patients in whom the potentialbenefit outweighs the risk.
• Established/FDA-approved use: Maintenance of normal sinus rhythm (delay in time torecurrence of atrial fibrillation/flutter) in patients with symptomatic atrial fibrillation or atrialflutter (AFib/AFl) who are currently in sinus rhythm.
• Guideline-supported (off-label) use: Sotalex is also used, under specialistcardiology supervision, for rate/rhythm control in select patients with recurrent atrial arrhythmiaswhen other agents are unsuitable.

Sotalex is not used for hypertension alone or as a first-line antiarrhythmic; therapy is initiated by,or in consultation with, a cardiologist.

Each tablet contains Sotalol Hydrochloride INN as the active pharmaceutical ingredient. Sotalol Hydrochloride is commonly available as oral tablets in strengths such as 40 mg, 80 mg, and 160 mg, and in some markets as an oral solution, for oral administration.

Sotalex is a synthetic, non-selective beta-adrenergic receptor blocking agent that alsopossesses Class III (cardiac action potential-prolonging) antiarrhythmic properties. This dual mechanismmakes Sotalex unique among antiarrhythmic drugs, as it combines rate-control (beta-blocking) effects withrhythm-control (potassium-channel blocking) effects. Sotalex is used in the management of seriousventricular arrhythmias and in maintaining sinus rhythm in patients with atrial fibrillation orflutter.

Antiarrhythmic agent, Class III (with non-selective Class II beta-adrenergic blocking activity)

Pharmacology

Sotalol Hydrochloride exhibits both Class II (beta-blocking) and Class III (potassium-channel blocking)antiarrhythmic properties, and is not chemically related to other antiarrhythmic agents.

• Class II activity: Sotalol Hydrochloride is a non-cardioselective competitive beta-adrenergicantagonist, reducing heart rate, myocardial contractility, and AV nodal conduction, and lowering reninrelease.
• Class III activity: Sotalol Hydrochloride blocks the rapid component of the delayed-rectifierpotassium current, prolonging the cardiac action potential and effective refractory period in atrial,ventricular, and AV nodal tissue, without significantly affecting conduction velocity. Thisprolongation is reflected clinically as dose-related QT-interval prolongation.

Pharmacokinetically, Sotalol Hydrochloride is well absorbed orally, is not appreciably protein-bound or hepaticallymetabolized, and is eliminated largely unchanged by the kidneys, which is why dosing must be adjustedfor renal function.

Sotalex tablets should be taken by mouth, consistently either with or without food (food may reduceabsorption slightly, so consistency is advised), and swallowed with water. Doses should be spaced evenly(e.g., every 12 hours). Antacids containing aluminum or magnesium should not be taken at the same time asSotalex, as they can reduce its absorption. Treatment with Sotalex should never be stopped abruptly withoutmedical advice (see Precautions and Warnings). The initial dose and any dose increase should be givenunder ECG monitoring as directed by the physician.

Drug Interactions

• Other QT-prolonging drugs (e.g., Class IA antiarrhythmics such as quinidine/procainamide, other Class III agents such as amiodarone, certain antipsychotics, macrolide antibiotics,and fluoroquinolones): concurrent use with Sotalex is generally avoided due to additive risk of QTprolongation and torsades de pointes.
• Calcium channel blockers (verapamil, diltiazem): additive negative effects on heartrate, AV conduction, and myocardial contractility; concurrent use with Sotalex requires caution, andintravenous use is generally avoided.
• Other beta-blockers or clonidine: additive bradycardia and hypotension with Sotalex;abrupt clonidine withdrawal during Sotalex therapy may cause exaggerated rebound hypertension.
• Drugs causing hypokalemia or hypomagnesemia (e.g., potassium-wasting diuretics):increase the risk of torsades de pointes when combined with Sotalex; electrolytes should be corrected andmonitored.
• Insulin and oral antidiabetic agents: Sotalex may mask the tachycardia and tremor thatnormally warn of hypoglycemia.
• Aluminum/magnesium antacids: can reduce absorption of Sotalex; separate dosing times.

Side Effects

Common: fatigue, dizziness, weakness, headache, dyspnea (shortness of breath),bradycardia (slow heart rate), palpitations, nausea, and diarrhea.

Serious (require prompt medical attention): proarrhythmia including torsades depointes and other life-threatening ventricular arrhythmias, marked bradycardia or heart block, worseningof heart failure, severe hypotension, and bronchospasm (particularly in patients with reactive airwaydisease). Sotalex therapy should be reassessed by a physician if any of these occur.

Pregnancy and Lactation

Pregnancy: Sotalex should be used during pregnancy only if clearly needed and thepotential benefit justifies the potential risk to the fetus, and only under specialist supervision.Beta-blockade from Sotalex can cause fetal/neonatal bradycardia, hypoglycemia, and other effects; if usedclose to delivery, the neonate should be monitored for these effects for the first days of life.

Lactation: Sotalex is excreted into breast milk in significant amounts. Breastfeedingwhile taking Sotalex should only be done after consulting a physician, with the infant monitored for signsof beta-blockade such as bradycardia or hypoglycemia.

Precautions and Warnings

Proarrhythmia (boxed warning): Sotalex can cause life-threatening ventriculararrhythmias, particularly torsades de pointes, related to the degree of QT-interval prolongation. Tominimize this risk, Sotalex should be initiated and dose-titrated in a setting with continuous ECGmonitoring and the ability to calculate creatinine clearance, especially for the antiarrhythmic/rhythm-control indication.

Renal function: because Sotalex is cleared renally, dose and interval must be adjustedto creatinine clearance; accumulation in renal impairment increases proarrhythmic risk (see Dosage andAdministration).

Electrolytes: hypokalemia or hypomagnesemia should be corrected before startingSotalex, as these increase the risk of torsades de pointes.

Do not stop abruptly: Sotalex should not be discontinued suddenly, particularly inpatients with underlying coronary artery disease, as abrupt withdrawal of beta-blockade may precipitateangina, arrhythmia, or myocardial infarction; discontinue only under medical guidance with gradualtapering.

Bronchospasm: due to its non-selective beta-blocking activity, Sotalex should be usedwith extreme caution, if at all, in patients with bronchospastic disease.

Diabetes: Sotalex may mask signs of hypoglycemia (such as tachycardia); blood glucoseshould be monitored closely in diabetic patients.

Heart failure/bradycardia: use with caution in patients with compensated heartfailure or conduction abnormalities; monitor for worsening bradycardia or heart failure symptoms.

Overdose

Overdose of Sotalex may cause severe bradycardia, hypotension, marked QT-interval prolongation, torsadesde pointes or other ventricular arrhythmias, cardiac failure, bronchospasm, and hypoglycemia. Suspectedoverdose of Sotalex is a medical emergency: seek immediate medical attention or contact emergency services/a poison control center. Treatment is supportive and undertaken in a hospital setting with continuousECG monitoring; management may include measures to support heart rate and blood pressure as directed bythe treating physician. Do not attempt to manage a Sotalex overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Use in Special Populations

• Renal impairment: Sotalex requires dose/interval adjustment based on creatinineclearance and is contraindicated for the atrial fibrillation/flutter indication when CrCl is below40 mL/min (see Dosage and Administration).
• Hepatic impairment: Sotalex undergoes minimal hepatic metabolism, so significantdosage adjustment is not usually required for hepatic impairment alone, but caution and physicianmonitoring are advised.
• Elderly patients: may have reduced renal function and increased sensitivity to thebradycardic and hypotensive effects of Sotalex; dose should be individualized and renal function assessed.
• Diabetic patients: Sotalex may mask symptoms of hypoglycemia; monitor blood glucoseclosely.
• Pediatric patients: see Pediatric Uses.

Sotalex is generally used as long-term, ongoing therapy for control of serious arrhythmias, for as longas the treating cardiologist determines it is needed and well tolerated. The need for continued therapywith Sotalex should be reassessed periodically, including reassessment of QTc, renal function, andelectrolytes. Treatment should not be stopped or the dose changed without medical advice, and anydiscontinuation should be tapered under medical supervision.

Class III antiarrhythmic agent with combined non-selective Class II (beta-adrenergic blocking) activity

Sotalol Hydrochloride acts through two complementary mechanisms. As a non-selective beta-adrenergic blocker (Class IIaction), it competitively blocks beta-1 and beta-2 receptors, reducing sinus node automaticity, AV nodalconduction velocity, heart rate, and myocardial contractility. As a Class III antiarrhythmic, Sotalol Hydrochloride blocksthe rapid component of the delayed-rectifier potassium channel (I_Kr), which prolongs the cardiac actionpotential duration and effective refractory period in atrial, ventricular, and accessory conductiontissue without significant effect on conduction velocity. Together, these actions suppress re-entrantand automatic arrhythmias and help maintain normal sinus rhythm, while the QT-prolonging effect of Sotalol Hydrochlorideis also responsible for its proarrhythmic risk.

B

Pediatric Uses

Sotalex (in oral solution form, in markets where available) has been studied and used in pediatricpatients for treatment of documented life-threatening ventricular arrhythmias, with dosing individualizedby body surface area and administered only under close specialist cardiology supervision with continuousECG monitoring, especially during initiation and dose titration. Safety and efficacy of Sotalex for themaintenance-of-sinus-rhythm (atrial fibrillation/flutter) indication have not been established inchildren. Sotalex should be used in pediatric patients only when clearly indicated and prescribed by apediatric cardiologist.